Results 181 to 190 of about 5,946,577 (342)
Molecular Oncology, EarlyView.TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach +8 more
wiley +1 more source
Application of nanodiagnostics in point-of-care tests for infectious diseases
International Journal of Nanomedicine, 2017 Yongzhong Wang,1 Li Yu,2 Xiaowei Kong,1 Leming Sun3 1Anhui Key Laboratory of Modern Biomanufacturing, School of Life Sciences, Anhui University, Hefei, Anhui, People’s Republic of China, 2Department of Microbiology and Parasitology, Anhui ...
Wang YZ, Yu L, Kong XW, Sun LM
doaj
Total Bilirubin Measurement by Photometry on a Blood Gas Analyzer: Potential for Use in Neonatal Testing at the Point of Care [PDF]
, 2001 Boris Rolinski +4 more
openalex +1 more source
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
Molecular Oncology, EarlyView.The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche +8 more
wiley +1 more source
Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients [PDF]
, 2001 M. Ferring +5 more
openalex +1 more source
Molecular Oncology, EarlyView.A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul +11 more
wiley +1 more source
ROM Plus®: accurate point-of-care detection of ruptured fetal membranes
Medical Devices: Evidence and Research, 2016 Ross W McQuivey,1 Jon E Block2 1Clinical Affairs, Clinical Innovations, Salt Lake City, UT, 2Independent Clinical Consultant, San Francisco, CA, USAAbstract: Accurate and timely diagnosis of rupture of fetal membranes is imperative to inform and guide ...
McQuivey RW, Block JE
doaj
Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing [PDF]
, 2001 Timo Piironen +6 more
openalex +1 more source
Point of care tests for hospital-acquired infections (HAIs) : economic analysis report [PDF]
A number of clinical/disease areas have been prioritised by the Technology Strategy Board (TSB) and Department of Health (DH) for the DIIA Innovation Platform.
Osipenko, Leeza, Szczepura, Ala
core
Molecular Oncology, EarlyView.Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva +5 more
wiley +1 more source